Astrana Health (NASDAQ:ASTH) Stock Rating Upgraded by Zacks Research

Astrana Health (NASDAQ:ASTH) was upgraded by analysts at Zacks Research from a “strong sell” rating to a “hold” rating in a research note issued to investors on Wednesday,Zacks.com reports.

ASTH has been the subject of a number of other reports. Barclays cut their target price on shares of Astrana Health from $36.00 to $26.00 and set an “equal weight” rating for the company in a report on Monday, November 24th. BTIG Research reduced their target price on shares of Astrana Health from $45.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, February 2nd. Weiss Ratings restated a “sell (d+)” rating on shares of Astrana Health in a research report on Monday, December 29th. Jefferies Financial Group reiterated a “buy” rating on shares of Astrana Health in a research report on Tuesday, November 25th. Finally, Needham & Company LLC began coverage on Astrana Health in a research note on Friday, December 12th. They issued a “buy” rating and a $28.00 price objective for the company. Five equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $35.33.

Astrana Health Price Performance

Shares of NASDAQ:ASTH traded up $0.93 during mid-day trading on Wednesday, reaching $24.18. The stock had a trading volume of 173,346 shares, compared to its average volume of 565,904. The business’s 50 day moving average price is $23.48 and its 200 day moving average price is $26.03. Astrana Health has a 1 year low of $18.08 and a 1 year high of $34.80. The company has a market cap of $1.36 billion, a P/E ratio of 52.53 and a beta of 0.91. The company has a current ratio of 1.40, a quick ratio of 1.40 and a debt-to-equity ratio of 1.25.

Astrana Health (NASDAQ:ASTH) last released its quarterly earnings results on Monday, March 2nd. The company reported $0.54 earnings per share for the quarter, beating the consensus estimate of $0.15 by $0.39. Astrana Health had a return on equity of 5.59% and a net margin of 0.71%.The business had revenue of $950.53 million during the quarter, compared to analysts’ expectations of $930.46 million. The firm’s revenue for the quarter was up 42.9% compared to the same quarter last year. During the same quarter last year, the business posted ($0.15) EPS. Research analysts expect that Astrana Health will post 1.15 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. Signaturefd LLC lifted its holdings in Astrana Health by 57.9% during the 4th quarter. Signaturefd LLC now owns 1,058 shares of the company’s stock valued at $26,000 after buying an additional 388 shares in the last quarter. GAMMA Investing LLC increased its position in shares of Astrana Health by 144.7% during the fourth quarter. GAMMA Investing LLC now owns 1,473 shares of the company’s stock worth $37,000 after acquiring an additional 871 shares during the period. Strs Ohio bought a new stake in shares of Astrana Health during the fourth quarter valued at approximately $40,000. Covestor Ltd boosted its holdings in shares of Astrana Health by 210.6% in the third quarter. Covestor Ltd now owns 3,233 shares of the company’s stock valued at $92,000 after purchasing an additional 2,192 shares during the period. Finally, Tower Research Capital LLC TRC grew its stake in Astrana Health by 323.3% in the second quarter. Tower Research Capital LLC TRC now owns 4,605 shares of the company’s stock worth $115,000 after purchasing an additional 3,517 shares in the last quarter. 52.77% of the stock is currently owned by institutional investors.

About Astrana Health

Astrana Health, Inc, Inc, a physician-centric technology-powered healthcare management company, provides medical care services in the United States. It operates through three segments: Care Partners, Care Delivery, and Care Enablement. The company is leveraging its proprietary population health management and healthcare delivery platform, operates an integrated, value-based healthcare model which empowers the providers in its network to deliver care to its patients. It offers care coordination services to patients, families, primary care physicians, specialists, acute care hospitals, alternative sites of inpatient care, physician groups, and health plans.